Reteplase versus alteplase for acute ischaemic stroke within 4.5 hours (RAISE) : rationale and design of a multicentre, prospective, randomised, open-label, blinded-endpoint, controlled phase 3 non-inferiority trial
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
BACKGROUND AND PURPOSE: Reteplase is the third generation of alternative thrombolytic agent. We hypothesis that reteplase will be non-inferior to alteplase in achieving excellent functional outcome at 90 days among eligible patients with acute ischaemic stroke.
METHODS AND DESIGN: Reteplase versus alteplase for acute ischaemic stroke within 4.5 hours (RAISE) trial is a multicentre, prospective, randomised, open-label, blinded endpoint (PROBE), controlled phase 3 non-inferiority trial. A total of 1412 eligible patients will be randomly assigned to receive either reteplase at a dose of 18 mg+ 18 mg or alteplase 0.9 mg/kg at a ratio of 1:1. An independent data monitoring committee will review the trail's progress and safety data.
STUDY OUTCOMES: The primary efficacy outcome of this study is proportion of individuals attaining an excellent functional outcome, defined as modified Rankin Scale (mRS) 0-1 at 90 days. The secondary efficacy outcomes encompass favourable functional outcome defined as mRS 0-2, major neurological improvement on the National Institutes of Health Stroke Scale, ordinal distribution of mRS and Barthel Index score of at least 95 points at 90 days. The primary safety outcomes are symptomatic intracranial haemorrhage at 36 hours within 90 days.
DISCUSSION: The RAISE trial will provide crucial insights into the selection of thrombolytic agents for stroke thrombolysis.
TRIAL REGISTRATION NUMBER: NCT05295173.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Stroke and vascular neurology - (2024) vom: 29. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Shuya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cerebral Infarction |
|---|
| Anmerkungen: |
Date Revised 29.01.2024 published: Print-Electronic ClinicalTrials.gov: NCT05295173 Citation Status Publisher |
|---|
| doi: |
10.1136/svn-2023-003035 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367768283 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367768283 | ||
| 003 | DE-627 | ||
| 005 | 20240130232235.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240130s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/svn-2023-003035 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1275.xml |
| 035 | |a (DE-627)NLM367768283 | ||
| 035 | |a (NLM)38286482 | ||
| 035 | |a (PII)svn-2023-003035 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Shuya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Reteplase versus alteplase for acute ischaemic stroke within 4.5 hours (RAISE) |b rationale and design of a multicentre, prospective, randomised, open-label, blinded-endpoint, controlled phase 3 non-inferiority trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT05295173 | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a BACKGROUND AND PURPOSE: Reteplase is the third generation of alternative thrombolytic agent. We hypothesis that reteplase will be non-inferior to alteplase in achieving excellent functional outcome at 90 days among eligible patients with acute ischaemic stroke | ||
| 520 | |a METHODS AND DESIGN: Reteplase versus alteplase for acute ischaemic stroke within 4.5 hours (RAISE) trial is a multicentre, prospective, randomised, open-label, blinded endpoint (PROBE), controlled phase 3 non-inferiority trial. A total of 1412 eligible patients will be randomly assigned to receive either reteplase at a dose of 18 mg+ 18 mg or alteplase 0.9 mg/kg at a ratio of 1:1. An independent data monitoring committee will review the trail's progress and safety data | ||
| 520 | |a STUDY OUTCOMES: The primary efficacy outcome of this study is proportion of individuals attaining an excellent functional outcome, defined as modified Rankin Scale (mRS) 0-1 at 90 days. The secondary efficacy outcomes encompass favourable functional outcome defined as mRS 0-2, major neurological improvement on the National Institutes of Health Stroke Scale, ordinal distribution of mRS and Barthel Index score of at least 95 points at 90 days. The primary safety outcomes are symptomatic intracranial haemorrhage at 36 hours within 90 days | ||
| 520 | |a DISCUSSION: The RAISE trial will provide crucial insights into the selection of thrombolytic agents for stroke thrombolysis | ||
| 520 | |a TRIAL REGISTRATION NUMBER: NCT05295173 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cerebral Infarction | |
| 650 | 4 | |a Stroke | |
| 650 | 4 | |a Thrombolytic Therapy | |
| 700 | 1 | |a Gu, Hong-Qiu |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Hongguo |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Guozhi |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yongjun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Stroke and vascular neurology |d 2016 |g (2024) vom: 29. Jan. |w (DE-627)NLM263633950 |x 2059-8696 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:29 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/svn-2023-003035 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 29 |c 01 | ||